A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

(2022) Rebecca Kristeleit et al.   LANCET ONCOLOGY

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

(2021) Andrés Poveda et al.   LANCET ONCOLOGY

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

(2021) Bradley J Monk et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Susana Banerjee et al.   LANCET ONCOLOGY

Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.

(2020) Mansoor Raza Mirza et al.   JOURNAL OF CLINICAL ONCOLOGY

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

(2020) Jonathan A Ledermann et al.   LANCET ONCOLOGY

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

(2019) Josep M. del Campo et al.   JOURNAL OF CLINICAL ONCOLOGY

Joint ENGOT and GOG Foundation requirements for trials with industry partners

(2019) Ignace Vergote et al.   GYNECOLOGIC ONCOLOGY

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2019) Antonio González-Martín et al.   NEW ENGLAND JOURNAL OF MEDICINE

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

(2019) Robert L. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

(2019) Isabelle Ray-Coquard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exaggeration of PFS by blinded, independent, central review (BICR)

(2018) A Stone et al.   ANNALS OF ONCOLOGY

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Robert L Coleman et al.   LANCET

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

(2017) Elizabeth M Swisher et al.   LANCET ONCOLOGY

On generalized fixed sequence procedures for controlling the FWER

(2015) Zhiying Qiu et al.   STATISTICS IN MEDICINE